Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor ⍺ receptor IgG1-Fc fusion complex therapy - 02/09/11
Abstract |
Tumor necrosis factor ⍺ (TNF-⍺) is now believed to be a major contributor to the pathogenesis of the synovitis and joint destruction in rheumatoid arthritis. Etanercept is a recombinant human TNF-⍺ receptor Fc fusion protein consisting of a dimer of the extracellular portion of two p75 TNF-⍺ receptors fused to the Fc portion of human IgG1. Etanercept produces significant dose-dependent improvements in disease activity. We describe 7 patients who experienced 1 or more squamous cell carcinomas that showed rapid growth and arose over a 2- to 4-month period of etanercept therapy. Soluble TNF-⍺ receptor therapy through inhibition of a TH1 cytokine pattern and inhibition of the direct and indirect cytotoxic effects of TNF-⍺ may initially decrease mechanisms for controlling subclinical tumors and may contribute to the histologic features seen within these tumors. However, prolonged TNF-⍺ inhibition may have some antitumor effects. (J Am Acad Dermatol 2001;45:953-6.)
Le texte complet de cet article est disponible en PDF.Plan
The opinions or assertions herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, the Department of the Navy, of the Department of Defense. |
|
Reprint requests: Kathleen J. Smith, MD, Department of Dermatology and Pathology, National Naval Medical Center, Bethesda, MD 20889-5600. |
Vol 45 - N° 6
P. 953-956 - décembre 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?